Hemab Therapeutics Holdings, Inc. IPO - What You Need to Know

Thinking about the Hemab Therapeutics IPO? Biotech investing is exciting, but the science and business side can get complicated. Let’s break down what this company does in plain English so you can decide if it fits your portfolio.

1. What does this company do?

Hemab focuses on "blood health." They are a clinical-stage biotechnology company creating specialized medicines for people with rare, life-long blood-clotting disorders. They target diseases where current treatments are either ineffective or carry high risks.

Their lead drug, sutacimig (HMB-001), acts like a bridge to help blood clot properly. They are testing it for two conditions: Glanzmann thrombasthenia and Factor VII deficiency. They also have HMB-002 in early testing for Von Willebrand Disease. Their goal is the "Hemab 2x3 by 2030" plan: to have two commercial medicines, two late-stage programs, and two early-stage programs by 2030.

2. How do they make money?

Hemab is currently in the research phase. They have never made a dollar from product sales. They are a "science-first" company spending heavily to reach the finish line. In 2025, they spent about $70 million on research and clinical trials, resulting in a $64 million loss. They rely entirely on outside funding to operate until they gain regulatory approval to sell their drugs.

3. What will they do with the IPO money?

Hemab hopes to raise about $180 million. This cash should fund their research through the second half of 2028. They will use it to advance sutacimig, including a Phase 3 trial in late 2026, and to move their other drug candidates forward. Because Phase 3 trials are very expensive, they will likely need to raise more money later to finish these studies and launch their products.

4. What are the main risks?

• The "All-or-Nothing" Risk: They have no approved products. If their trials fail, the company’s value could drop significantly.
• The "Money Pit" Reality: They have an "accumulated deficit" of $181.9 million. They have spent $182 million more than they have earned, and they expect these losses to continue for years.
• Tax Hurdles: Operating in Denmark and the U.S. creates complex tax risks. They have $170.9 million in tax losses they hope to use to lower future taxes. However, if the company’s ownership changes, they might lose the ability to use these tax breaks.
• Regulatory Uncertainty: They plan a "single-arm" Phase 3 trial, which uses historical data instead of a placebo group. If regulators demand a more complex, randomized trial, it could cause massive delays and higher costs.
• Dilution: To keep operating, they will likely issue more shares. This reduces your ownership percentage and may lower the value of your shares.

5. Who is running the company?

Dr. Benny Sørensen serves as CEO. The leadership team includes experts who have helped bring other blood-disorder drugs to market. While this experience is a plus, past success does not guarantee that Hemab’s current drugs will pass clinical trials.

6. Where will it trade and what will it cost?

Hemab plans to list on the Nasdaq under the ticker "COAG." They estimate a price range of $16.00 to $18.00 per share.

Final Thoughts: Is this for you?

Investing in a company like Hemab is essentially a bet on their clinical trial results. If their drugs work, they could change the standard of care for rare blood disorders. If they don't, the company has little else to fall back on.

Before you buy:

1. Check the Prospectus: Look for the "Risk Factors" section in their official SEC filing. It’s long, but it’s the most honest document they have.
2. Know your timeline: This is not a "get rich quick" stock. It is a long-term play that will likely see significant price swings as trial results are announced.
3. Size your position: Because of the high risk of failure, many investors keep biotech bets to a small percentage of their total portfolio.

Disclaimer: I am an AI, not a financial advisor. Biotech IPOs are high-risk. Never invest money you cannot afford to lose.